{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:41:58Z","timestamp":1792021318277,"version":"4.4.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA023100"],"award-info":[{"award-number":["P30 CA023100"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.trecan.2020.11.002","type":"journal-article","created":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T21:59:25Z","timestamp":1611784765000},"page":"465-477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Cancer of Unknown Primary in the Molecular Era"],"prefix":"10.1016","volume":"7","author":[{"given":"Shumei","family":"Kato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Alsafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vighnesh","family":"Walavalkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hainsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2020.11.002_bb0005","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/S0959-8049(03)00547-1","article-title":"Diagnostic and therapeutic management of cancer of an unknown primary","volume":"39","author":"Pavlidis","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.trecan.2020.11.002_bb0010","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S0140-6736(11)61178-1","article-title":"Cancer of unknown primary site","volume":"379","author":"Pavlidis","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2020.11.002_bb0015","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s41669-017-0051-2","article-title":"The potential clinical and economic value of primary tumour identification in metastatic cancer of unknown primary tumour: a population-based retrospective matched cohort study","volume":"2","author":"Hannouf","year":"2018","journal-title":"Pharmacoecon. Open"},{"key":"10.1016\/j.trecan.2020.11.002_bb0020","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.18.00771","article-title":"Randomized phase II trial comparing site-specific treatment based on gene expression profiling with carboplatin and paclitaxel for patients with cancer of unknown primary site","volume":"37","author":"Hayashi","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2020.11.002_bb0025","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1200\/JCO.2003.12.104","article-title":"Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01)","volume":"21","author":"Culine","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2020.11.002_bb0030","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1200\/JCO.2000.18.17.3101","article-title":"Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study","volume":"18","author":"Briasoulis","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2020.11.002_bb0035","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMra1303917","article-title":"Carcinoma of unknown primary site","volume":"371","author":"Varadhachary","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2020.11.002_bb0040","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1200\/JCO.2007.14.4378","article-title":"Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation","volume":"26","author":"Varadhachary","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2020.11.002_bb0045","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1200\/JCO.2012.43.3755","article-title":"Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute","volume":"31","author":"Hainsworth","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2020.11.002_bb0050","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ctrv.2009.05.005","article-title":"Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis","volume":"35","author":"Golfinopoulos","year":"2009","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.trecan.2020.11.002_bb0055","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1158\/0008-5472.CAN-17-0628","article-title":"Utility of genomic analysis in circulating tumor DNA from patients with carcinoma of unknown primary","volume":"77","author":"Kato","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2020.11.002_bb0060","series-title":"Encyclopedia of Food Sciences and Nutrition","first-page":"3917","article-title":"Microscopy. Light microscopy and histochemical methods","author":"Holgate","year":"2003"},{"key":"10.1016\/j.trecan.2020.11.002_bb0065","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/cancers10040108","article-title":"Immunohistochemistry for diagnosis of metastatic carcinomas of unknown primary site","volume":"10","author":"Selves","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.trecan.2020.11.002_bb0070","doi-asserted-by":"crossref","first-page":"v133","DOI":"10.1093\/annonc\/mdv305","article-title":"Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Fizazi","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2020.11.002_bb0075","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ygyno.2015.01.541","article-title":"Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas","volume":"137","author":"McConechy","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.trecan.2020.11.002_bb0080","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10555-015-9552-6","article-title":"HER2 expression status in diverse cancers: review of results from 37,992 patients","volume":"34","author":"Yan","year":"2015","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.trecan.2020.11.002_bb0085","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/9795269","article-title":"Clinically meaningful use of blood tumor markers in oncology","volume":"2016","author":"Holdenrieder","year":"2016","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.trecan.2020.11.002_bb0090","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/BF02968047","article-title":"Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: a prospective study","volume":"11","author":"Kurebayashi","year":"2004","journal-title":"Breast Cancer"},{"key":"10.1016\/j.trecan.2020.11.002_bb0095","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/mpo.2950220303","article-title":"Evaluation of six tumor markers in patients with carcinoma of unknown primary","volume":"22","author":"Pavlidis","year":"1994","journal-title":"Med. Pediatr. Oncol."},{"key":"10.1016\/j.trecan.2020.11.002_bb0100","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4103\/0975-5950.196135","article-title":"Tumor markers: a diagnostic tool. Natl","volume":"7","author":"Nagpal","year":"2016","journal-title":"J. Maxillofac. Surg."},{"key":"10.1016\/j.trecan.2020.11.002_bb0105","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1093\/annonc\/mdt177","article-title":"Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy","volume":"24","author":"Kurzrock","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2020.11.002_bb0110","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1158\/1078-0432.CCR-10-2599","article-title":"Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary","volume":"17","author":"Varadhachary","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2020.11.002_bb0115","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(16)30297-2","article-title":"Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis","volume":"17","author":"Moran","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2020.11.002_bb0120","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1634\/theoncologist.2009-0328","article-title":"Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction","volume":"15","author":"Greco","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.trecan.2020.11.002_bb0125","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1200\/JCO.2007.14.6969","article-title":"Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary","volume":"26","author":"Horlings","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2020.11.002_bb0130","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/sj.bjc.6604315","article-title":"Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary","volume":"98","author":"Bridgewater","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.trecan.2020.11.002_bb0135","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jmoldx.2010.11.001","article-title":"Validation and reproducibility of a microarray-based gene expression test for tumor identification in formalin-fixed, paraffin-embedded specimens","volume":"13","author":"Pillai","year":"2011","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.trecan.2020.11.002_bb0140","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz394","article-title":"LBA15_PR a phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)","volume":"30","author":"Fizazi","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2020.11.002_bb0145","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejca.2019.12.016","article-title":"The role of site-specific therapy for cancers of unknown of primary: a meta-analysis","volume":"127","author":"Rassy","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.trecan.2020.11.002_bb0150","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jamaoncol.2014.216","article-title":"Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies","volume":"1","author":"Ross","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.trecan.2020.11.002_bb0155","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/path.4251","article-title":"Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary","volume":"231","author":"Tothill","year":"2013","journal-title":"J. Pathol."},{"key":"10.1016\/j.trecan.2020.11.002_bb0160","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejca.2018.02.021","article-title":"Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy","volume":"94","author":"Gatalica","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.trecan.2020.11.002_bb0165","doi-asserted-by":"crossref","first-page":"44322","DOI":"10.18632\/oncotarget.10035","article-title":"Molecular driver alterations and their clinical relevance in cancer of unknown primary site","volume":"7","author":"Loffler","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.trecan.2020.11.002_bb0170","doi-asserted-by":"crossref","first-page":"12440","DOI":"10.18632\/oncotarget.2574","article-title":"Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases","volume":"5","author":"Gatalica","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.trecan.2020.11.002_bb0175","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1093\/annonc\/mdx545","article-title":"Clinical and molecular characterization of patients with cancer of unknown primary in the modern era","volume":"28","author":"Varghese","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2020.11.002_bb0180","doi-asserted-by":"crossref","first-page":"e9942","DOI":"10.1097\/MD.0000000000009942","article-title":"Putative lung adenocarcinoma with epidermal growth factor receptor mutation presenting as carcinoma of unknown primary site: a case report","volume":"97","author":"Yamasaki","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.trecan.2020.11.002_bb0185","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1200\/JCO.2012.44.3937","article-title":"Molecular profiling for druggable genetic abnormalities in carcinoma of unknown primary","volume":"31","author":"Tan","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2020.11.002_bb0190","first-page":"1030","article-title":"Lung cancer of unknown primary site with EGFR mutation as indicated by frozen bone specimen","volume":"2","author":"Boku","year":"2015","journal-title":"J. Pulm. Respir. Med."},{"key":"10.1016\/j.trecan.2020.11.002_bb0195","first-page":"1291","article-title":"Cancer of unknown primary site with epidermal growth factor receptor mutation for which gefitinib proved effective","volume":"39","author":"Yamada","year":"2012","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.trecan.2020.11.002_bb0200","doi-asserted-by":"crossref","first-page":"35278","DOI":"10.18632\/oncotarget.26233","article-title":"ROS1-rearranged putative lung adenocarcinoma presenting as carcinoma of unknown primary site: a case report","volume":"9","author":"Taniwaki","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.trecan.2020.11.002_bb0205","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40801-016-0064-7","article-title":"Lung adenocarcinoma with anaplastic lymphoma kinase (ALK) rearrangement presenting as carcinoma of unknown primary site recognition and treatment implications","volume":"3","author":"Hainsworth","year":"2016","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.trecan.2020.11.002_bb0210","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1159\/000367780","article-title":"A poorly differentiated malignant neoplasm lacking lung markers harbors an EML4-ALK rearrangement and responds to crizotinib","volume":"7","author":"Chung","year":"2014","journal-title":"Case Rep. Oncol."},{"key":"10.1016\/j.trecan.2020.11.002_bb0215","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy279.432","article-title":"445TiP comprehensive profiling and molecularly guided therapy (MGT) for carcinomas of unknown primary (CUP): CUPISCO: a phase II, randomised, multicentre study comparing targeted therapy or immunotherapy with standard platinum-based chemotherapy","volume":"29","author":"Kr\u00e4mer","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2020.11.002_bb0220","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2020.11.002_bb0225","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamaoncol.2018.1701","article-title":"Prevalence of PDL1 amplification and preliminary response to immune checkpoint blockade in solid tumors","volume":"4","author":"Goodman","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.trecan.2020.11.002_bb0230","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.trecan.2020.11.002_bb0235","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1158\/2326-6066.CIR-19-0149","article-title":"Microsatellite-stable tumors with high mutational burden benefit from immunotherapy","volume":"7","author":"Goodman","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.trecan.2020.11.002_bb0240","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.trecan.2020.11.002_bb0245","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","article-title":"Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate","volume":"23","author":"Kato","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2020.11.002_bb0250","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000347","article-title":"Phase 2 study of pembrolizumab in patients with advanced rare cancers","volume":"8","author":"Naing","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2020.11.002_bb0255","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2020.11.002_bb0260","article-title":"Revisiting epidermal growth factor receptor (EGFR) amplification as a target for anti-EGFR therapy: analysis of cell-free circulating tumor DNA in patients with advanced malignancies","volume":"3","author":"Kato","year":"2019","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.trecan.2020.11.002_bb0265","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2017.75.3780","article-title":"Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study","volume":"36","author":"Hainsworth","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2020.11.002_bb0270","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jtho.2017.01.023","article-title":"ERBB2-mutated metastatic non-small cell lung cancer: response and resistance to targeted therapies","volume":"12","author":"Chuang","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.trecan.2020.11.002_bb0275","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3390\/cells8080793","article-title":"Short overview of ROS as cell function regulators and their implications in therapy concepts","volume":"8","author":"Milkovic","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.trecan.2020.11.002_bb0280","series-title":"FDA Expands Use of Xalkori to Treat Rare Form of Advanced Non-small Cell Lung Cancer","author":"U.S. Food and Drug Administration","year":"2016"},{"key":"10.1016\/j.trecan.2020.11.002_bb0285","article-title":"Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics","volume":"2018","author":"Okamura","year":"2018","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.trecan.2020.11.002_bb0290","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2020.11.002_bb0295","series-title":"FDA Approves Larotrectinib for Solid Tumors with NTRK Gene Fusions","author":"U.S. Food and Drug Administration","year":"2018"},{"key":"10.1016\/j.trecan.2020.11.002_bb0300","series-title":"FDA Approves Entrectinib for NTRK Solid Tumors and ROS-1 NSCLC","author":"U.S. Food and Drug Administration","year":"2019"},{"key":"10.1016\/j.trecan.2020.11.002_bb0305","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41379-018-0118-3","article-title":"Molecular characterization of cancers with NTRK gene fusions","volume":"32","author":"Gatalica","year":"2019","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.trecan.2020.11.002_bb0310","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2020.11.002_bb0315","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1002\/ijc.32813","article-title":"Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies","volume":"146","author":"Kato","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.trecan.2020.11.002_bb0320","first-page":"96","article-title":"The MAPK (ERK) pathway: investigational combinations for the treatment of BRAF-mutated metastatic melanoma","volume":"38","author":"McCain","year":"2013","journal-title":"P T"},{"key":"10.1016\/j.trecan.2020.11.002_bb0325","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.2019.37.15_suppl.3003","article-title":"Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors","volume":"37","author":"Fakih","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2020.11.002_bb0330","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz244.008","article-title":"446PD phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours","volume":"30","author":"Govindan","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2020.11.002_bb0335","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRASG12C inhibitor, MRTX849, provides insight toward therapeutic susceptibility of KRAS mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2020.11.002_bb0340","first-page":"988","volume":"9","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2020.11.002_bb0345","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2017.3438","article-title":"Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: the SELECT-1 randomized clinical trial","volume":"317","author":"Janne","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.trecan.2020.11.002_bb0350","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jamaoncol.2016.5383","article-title":"Effect of selumetinib and MK-2206 vs oxaliplatin and fluorouracil in patients with metastatic pancreatic cancer after prior therapy: SWOG S1115 study randomized clinical trial","volume":"3","author":"Chung","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.trecan.2020.11.002_bb0355","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1056\/NEJMc1713676","article-title":"Rosai-Dorfman disease with activating KRAS mutation - response to cobimetinib","volume":"377","author":"Jacobsen","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2020.11.002_bb0360","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2020.11.002_bb0365","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2020.11.002_bb0370","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2020.11.002_bb0375","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1080\/15384101.2015.1041695","article-title":"Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes","volume":"14","author":"Kurzrock","year":"2015","journal-title":"Cell Cycle"},{"key":"10.1016\/j.trecan.2020.11.002_bb0380","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","article-title":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study","volume":"25","author":"Sicklick","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2020.11.002_bb0385","doi-asserted-by":"crossref","first-page":"127","DOI":"10.14694\/EdBook_AM.2013.33.127","article-title":"Molecular profiling and the reclassification of cancer: divide and conquer","volume":"2013","author":"Munoz","year":"2013","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.trecan.2020.11.002_bb0390","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.5858\/arpa.2014-0061-RA","article-title":"Immunohistochemistry in undifferentiated neoplasm\/tumor of uncertain origin","volume":"138","author":"Lin","year":"2014","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.trecan.2020.11.002_bb0395","doi-asserted-by":"crossref","first-page":"508","DOI":"10.5858\/arpa.2015-0173-CP","article-title":"Practical applications in immunohistochemistry: carcinomas of unknown primary site","volume":"140","author":"Kandalaft","year":"2016","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.trecan.2020.11.002_bb0400","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/jcp.2004.018291","article-title":"Expression of prostate specific antigen in male breast cancer","volume":"58","author":"Carder","year":"2005","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.trecan.2020.11.002_bb0405","doi-asserted-by":"crossref","first-page":"620","DOI":"10.18632\/oncotarget.521","article-title":"Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer: impact on diagnosis, treatment, and survival","volume":"3","author":"Nystrom","year":"2012","journal-title":"Oncotarget"}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803320303010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803320303010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:53:36Z","timestamp":1762505616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803320303010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":81,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S2405803320303010"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2020.11.002","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer of Unknown Primary in the Molecular Era","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2020.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}